| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1041667446 |
| P356 | DOI | 10.1007/S10741-009-9153-Y |
| P932 | PMC publication ID | 2772951 |
| P698 | PubMed publication ID | 19876734 |
| P5875 | ResearchGate publication ID | 38055176 |
| P50 | author | Marco Metra | Q39274051 |
| Mihai Gheorghiade | Q60059386 | ||
| John R Teerlink | Q90422543 | ||
| Valerio Zacà | Q90900221 | ||
| Hani N Sabbah | Q114291627 | ||
| Gadi Cotter | Q114321731 | ||
| Livio Dei Cas | Q114321778 | ||
| P2860 | cites work | 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration | Q22306346 |
| Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial | Q28300233 | ||
| Medical management of advanced heart failure | Q31037482 | ||
| Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group | Q33157410 | ||
| Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial | Q33978533 | ||
| Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology | Q34389554 | ||
| Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial | Q34474439 | ||
| A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators | Q34483643 | ||
| Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure | Q34530451 | ||
| Contemporary use of digoxin in the management of cardiovascular disorders | Q34532122 | ||
| Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). | Q34557005 | ||
| Nationwide survey on acute heart failure in cardiology ward services in Italy | Q34566380 | ||
| EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population | Q34568746 | ||
| Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure | Q34572385 | ||
| The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis | Q34776831 | ||
| Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy | Q34819581 | ||
| Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization | Q35183082 | ||
| Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy | Q35186772 | ||
| Overview of randomized clinical trials in acute heart failure syndromes | Q36266723 | ||
| Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. | Q36357779 | ||
| Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline | Q36406212 | ||
| Evidence-based use of levosimendan in different clinical settings | Q36472079 | ||
| Emerging therapies for the management of decompensated heart failure: from bench to bedside | Q36686323 | ||
| Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology | Q36811824 | ||
| Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial | Q36835915 | ||
| Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure | Q37038947 | ||
| Overview of emerging pharmacologic agents for acute heart failure syndromes | Q37086309 | ||
| Acute heart failure syndromes and coronary perfusion | Q37200978 | ||
| Metabolic therapy of heart failure | Q37320396 | ||
| Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. | Q37364786 | ||
| Acute heart failure syndromes | Q37392540 | ||
| A novel approach to improve cardiac performance: cardiac myosin activators | Q37398701 | ||
| Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? | Q37399996 | ||
| Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology | Q37455607 | ||
| Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope | Q39300182 | ||
| Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure | Q40586285 | ||
| Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials | Q41859441 | ||
| Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. | Q43266259 | ||
| Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial | Q43930568 | ||
| Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol | Q44182274 | ||
| Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study | Q44371716 | ||
| Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure | Q44399379 | ||
| Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial | Q44732752 | ||
| Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure | Q45167544 | ||
| Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. | Q45878067 | ||
| Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Tria | Q45999393 | ||
| Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure | Q46556129 | ||
| In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). | Q46578814 | ||
| Rationale and design of the enoximone clinical trials program | Q46856112 | ||
| Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database | Q46874074 | ||
| Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). | Q53344976 | ||
| ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology | Q55050673 | ||
| Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group | Q57396271 | ||
| Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation | Q70467387 | ||
| Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors | Q72050272 | ||
| Association of serum digoxin concentration and outcomes in patients with heart failure | Q73004928 | ||
| The effect of digoxin on mortality and morbidity in patients with heart failure | Q73080377 | ||
| Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial | Q78061912 | ||
| Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure | Q79615255 | ||
| INTERMACS profiles of advanced heart failure: the current picture | Q83948628 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| cardiotonic | Q2938102 | ||
| acute decompensated heart failure | Q4677930 | ||
| P304 | page(s) | 243-53 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Heart Failure Reviews | Q2167497 |
| P1476 | title | Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond | |
| P478 | volume | 14 |
| Q34995668 | 2-Deoxy adenosine triphosphate improves contraction in human end-stage heart failure |
| Q41115730 | A single German center experience with intermittent inotropes for patients on the high-urgent heart transplant waiting list |
| Q36756838 | AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility. |
| Q40562358 | Authors' reply concerning the letter by Ensminger et al. |
| Q37851240 | Cardiac inotropes: current agents and future directions |
| Q55025652 | Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil. |
| Q91713842 | Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte |
| Q28085736 | Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs |
| Q28242602 | Computer-aided drug discovery approach finds calcium sensitizer of cardiac troponin |
| Q34209528 | Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study |
| Q37783956 | Emerging therapies for heart failure: renal mechanisms and effects |
| Q49907634 | Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes. |
| Q56210548 | Heart failure |
| Q42198249 | Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart |
| Q35077700 | Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiology |
| Q58371157 | Intravenous therapies in acute heart failure–lack of effect or lack of well powered studies? |
| Q36527731 | Istaroxime: A rising star in acute heart failure |
| Q53511466 | Levosimendan improves hemodynamic status in critically ill patients with severe aortic stenosis and left ventricular dysfunction: an interventional study. |
| Q36173019 | Na(+)/K)+)-ATPase α2-isoform preferentially modulates Ca2(+) transients and sarcoplasmic reticulum Ca2(+) release in cardiac myocytes |
| Q37893956 | Novel therapeutic targets for the treatment of heart failure. |
| Q48049889 | Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle |
| Q38286038 | Pharmacogenetics of cardiac inotropy |
| Q36460566 | Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications |
| Q40964821 | Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure |
| Q37314355 | Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study |
| Q90446344 | Shock - Classification and Pathophysiological Principles of Therapeutics |
| Q21131829 | The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium |
| Q38870685 | The myosin activator omecamtiv mecarbil: a promising new inotropic agent |
| Q50668367 | Thoracic spinal cord stimulation improves cardiac contractile function and myocardial oxygen consumption in a porcine model of ischemic heart failure. |
| Q33728779 | Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy |
| Q92895515 | Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial |
| Q59684149 | Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation |
| Q38055287 | Ultrafiltration therapy for cardiorenal syndrome: physiologic basis and contemporary options |
| Q37858515 | Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents |
Search more.